Sana Biotechnology, Inc. Capital Expenditures Incurred but Not yet Paid
Sana Biotechnology, Inc. (SANA) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-03-03
- Sana Biotechnology, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $0.00.
- Sana Biotechnology, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $0.00.
- Sana Biotechnology, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was $0.00.
- Sana Biotechnology, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Sana Biotechnology, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $0.00.
- Sana Biotechnology, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Sana Biotechnology, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $9.47M, a 667.50% increase from fiscal 2022.
- Sana Biotechnology, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $1.23M, a 59.07% decline from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $0.00 10-K · filed 2026-03-03 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | -$258.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | -$258.00K derived: sum of 3 quarters · filed 2026-03-03 | -$3.38M derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | -$258.00K derived: sum of 2 quarters · filed 2026-03-03 | -$3.38M derived: sum of 3 quarters · filed 2026-03-03 | -$8.38M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-12-31 | -$258.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$3.38M derived: sum of 2 quarters · filed 2026-03-03 | -$8.38M derived: sum of 3 quarters · filed 2026-03-03 | $0.00 10-K · filed 2026-03-03 |
| 2024-09-30 | -$3.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$8.12M derived: sum of 2 quarters · filed 2025-11-06 | $258.00K 10-Q · filed 2025-11-06 | -$204.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | -$5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $3.38M 10-Q · filed 2025-08-11 | $2.91M derived: sum of 3 quarters · filed 2026-03-03 | $10.89M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $8.38M 10-Q · filed 2025-05-08 | $7.91M derived: sum of 2 quarters · filed 2026-03-03 | $15.89M derived: sum of 3 quarters · filed 2026-03-03 | $16.88M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | -$462.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $7.52M derived: sum of 2 quarters · filed 2026-03-03 | $8.50M derived: sum of 3 quarters · filed 2026-03-03 | $9.47M 10-K · filed 2026-03-03 |
| 2023-09-30 | $7.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $8.96M derived: sum of 2 quarters · filed 2024-11-08 | $9.93M 10-Q · filed 2024-11-08 | $8.76M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $985.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.95M 10-Q · filed 2024-08-08 | $778.00K derived: sum of 3 quarters · filed 2025-03-17 | -$159.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $968.00K 10-Q · filed 2024-05-08 | -$207.00K derived: sum of 2 quarters · filed 2025-03-17 | -$1.14M derived: sum of 3 quarters · filed 2025-03-17 | -$1.22M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | -$1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$2.11M derived: sum of 2 quarters · filed 2025-03-17 | -$2.19M derived: sum of 3 quarters · filed 2025-03-17 | $1.23M 10-K · filed 2025-03-17 |
| 2022-09-30 | -$937.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$1.02M derived: sum of 2 quarters · filed 2023-11-08 | $2.41M 10-Q · filed 2023-11-08 | $2.19M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $3.35M 10-Q · filed 2023-08-03 | $3.13M derived: sum of 3 quarters · filed 2024-02-29 | $2.95M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $3.42M 10-Q · filed 2023-05-08 | $3.21M derived: sum of 2 quarters · filed 2024-02-29 | $3.03M derived: sum of 3 quarters · filed 2024-02-29 | $3.28M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$216.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$399.00K derived: sum of 2 quarters · filed 2024-02-29 | -$142.00K derived: sum of 3 quarters · filed 2024-02-29 | $3.02M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$183.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $74.00K derived: sum of 2 quarters · filed 2022-11-02 | $3.23M 10-Q · filed 2022-11-02 | $2.13M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $257.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $3.41M 10-Q · filed 2022-08-04 | $2.32M derived: sum of 3 quarters · filed 2023-03-16 | $4.26M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $3.16M 10-Q · filed 2022-05-10 | $2.06M derived: sum of 2 quarters · filed 2023-03-16 | $4.01M derived: sum of 3 quarters · filed 2023-03-16 | $5.65M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $851.00K derived: sum of 2 quarters · filed 2023-03-16 | $2.50M derived: sum of 3 quarters · filed 2023-03-16 | $3.14M 10-K · filed 2023-03-16 |
| 2020-09-30 | $1.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $3.59M derived: sum of 2 quarters · filed 2021-11-08 | $4.24M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $2.29M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $644.00K 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $2.50M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |